FilingSEC EDGAR8-K
Aquestive Therapeutics Reports Q3 Results and Enters Libervant Licensing Agreement
· SEC accepted
Stageresults
Filing content
The company reported Q3 results and entered into a licensing agreement for Libervant, receiving a $10 million upfront payment.
AI summary of the filing. Please also check the source.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…